Composition containing pear syrup and preparation method thereof

Abstract

The invention discloses a composition containing pear syrup and a preparation method of the composition, and belongs to the technical field of supplementary food. The composition containing the pear syrup comprises the following raw materials: autumn pear syrup, concentrated apple juice, fermented mangosteen juice, hippophae rhamnoides fruit primary pulp and plant composite powder. In addition, the specific embodiment of the invention also provides a preparation method of the composition containing the pear syrup, and the preparation method comprises the following steps: mixing the autumn pear syrup, the concentrated apple juice and the fermented mangosteen juice, and boiling at 80-85 DEG C; adding a roxburgh rose extracting solution, decocting at 90-95 DEG C, adding plant composite powder at 105-108 DEG C, and stirring to obtain the composition containing the pear syrup. The composition provided by the invention has excellent effects of decreasing internal heat and diminishing inflammation.

Description

Technical Field

[0001] The present invention relates to the technical field of supplementary foods, and in particular to a composition containing pear paste and a preparation method thereof. Background Art

[0002] Infancy is a crucial period of growth and development for the human body, and nutritional levels during this period directly impact physical development in adolescence and adulthood. Breast milk is the ideal food for infants and young children, but for a small number of mothers unable to breastfeed due to illness, insufficient milk production, or no milk production, formula milk and complementary foods are needed to provide the nutrients necessary for their growth and development. Breast milk is the ideal food for infants and young children, but for a small number of mothers unable to breastfeed due to illness, insufficient milk production, or no milk production, formula milk and complementary foods are needed to provide the nutrients necessary for their growth and development.

[0003] From a physiological developmental perspective, infants' organs and systems are not yet mature. Regarding their digestive system, their spleen and stomach function is relatively weak. Improper feeding, such as over-concentrated formula, excessive feeding, or overly greasy or warm complementary foods, can easily overburden the spleen and stomach, leading to food stagnation and, in turn, symptoms of "heatiness" (heatiness) such as bloating, constipation, and mouth sores. Regarding their immune system, infants' immune function is not yet fully developed, and their mucosal barriers, including those of the skin, respiratory tract, and digestive tract, are relatively weak, making them susceptible to invasion by pathogens such as bacteria and viruses, triggering inflammatory responses such as mouth ulcers, sore throats, and skin rashes.

[0004] Therefore, the preparation of supplementary food for reducing internal heat and inflammation suitable for infants and young children is a technical problem that needs to be solved in the prior art. Summary of the Invention

[0005] The purpose of the present invention is to overcome the above-mentioned technical deficiencies, provide a composition comprising pear paste and a preparation method thereof, and solve the technical problem in the prior art of developing supplementary foods suitable for reducing fire and inflammation in infants and young children.

[0006] In order to achieve the above technical objectives, the technical solution of the present invention provides a composition comprising pear paste, the raw materials of which include Qiuyue pear paste, concentrated apple juice, fermented mangosteen juice, sea buckthorn puree and plant composite powder.

[0007] In any embodiment, the composition, calculated by weight, comprises 40-50 parts of Qiuyue pear paste, 40-50 parts of concentrated apple juice, 4-8 parts of fermented mangosteen juice, 2-5 parts of sea buckthorn puree, and 0.5-0.7 parts of plant composite powder.

[0008] In any embodiment, the plant composite powder includes tangerine peel powder, lotus seed powder, emblica powder and chrysanthemum powder.

[0009] In any embodiment, in the plant composite powder, the mass ratio of the tangerine peel powder, the lotus seed powder, the emblica powder and the chrysanthemum powder is 1:(1-1.5):(0.5-0.8):(0.3-0.5).

[0010] In addition, this specific embodiment also proposes a method for preparing the above-mentioned composition containing pear paste, comprising the following steps:

[0011] Qiuyue pear paste, concentrated apple juice and fermented mangosteen juice are mixed and boiled at 80-85° C.; then, a sea buckthorn extract is added and boiled at 90-95° C.; then, plant composite powder is added and stirred at 105-108° C. to obtain the composition containing pear paste.

[0012] In any embodiment, the cooking time at 80-85° C. is 50-60 min; and / or the cooking time at 90-95° C. is 20-30 min; and / or the stirring time at 105-108° C. is 5-10 min.

[0013] In any embodiment, the concentrated apple juice is prepared by the following steps: squeezing apples to obtain apple juice, then adding pectinase to the apple juice, keeping it warm at 45-55°C for enzymolysis, then inactivating the enzyme, and then filtering and concentrating to obtain the concentrated apple juice.

[0014] In any embodiment, the added amount of the pectinase is 0.2-0.3% of the mass of the apple juice.

[0015] In any embodiment, the fermented mangosteen juice is prepared by the following steps: inoculating Lactobacillus plantarum into mangosteen juice and fermenting at 25-30° C., followed by inactivation to obtain the fermented mangosteen juice.

[0016] In any embodiment, the roxburghii puree is obtained by the following steps: mixing the roxburghii and water, extracting at 45-50° C., then filtering to obtain a water extract and a filter residue, mixing the filter residue with ethanol having a mass concentration of 50-60% at 50-55° C. and continuing to extract to obtain an ethanol extract, mixing the water extract and the ethanol extract, and then concentrating to obtain the roxburghii puree.

[0017] Compared with the prior art, the present invention has the following beneficial effects: Based on the construction of an acute inflammation model in mice, the present invention systematically investigated the anti-inflammatory effects of the composition proposed in the present invention. The results confirmed that the composition has significant anti-inflammatory and heat-reducing effects, the mechanism of which may be related to the inhibition of the expression of IL-1β, IL-13, IL-6, TNF-α, etc. The significant inhibitory effect on inflammatory factors in the LPS-induced acute inflammation model in mice (significant reduction in IL-1β, IL-13, IL-6, and TNF-α levels) indicates its anti-inflammatory effects. Furthermore, studies have shown that LPS-induced liver CAT, SOD, and AOC activities in mice significantly decreased, while MDA content significantly increased, indicating significant oxidative stress. In the composition, CAT, SOD, and AOC activities were significantly increased, while MDA content was significantly decreased. Furthermore, the increase in antioxidant enzyme activity became more pronounced with increasing pear paste dosage. This suggests that the composition has a protective effect in the anti-oxidative process. Liver HE staining also demonstrated that the composition has excellent anti-inflammatory effects. Furthermore, the composition proposed in the present invention has excellent anti-inflammatory and heat-reducing effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 1 is a graph showing the liver coefficient results of mice in each experimental group in the relevant tests of the present invention.

[0019] Figure 2 This is a graph showing the spleen coefficient results of mice in each experimental group in the relevant tests of the present invention.

[0020] Figure 3 1 is a graph showing the lung coefficient results of mice in each experimental group in the relevant tests of the present invention.

[0021] Figure 4 1 is a graph showing the mouse kidney coefficient results of each experimental group in the relevant tests of the present invention.

[0022] Figure 5 This is a graph showing the IL-13 content in the serum of mice in each experimental group in the relevant test of the present invention.

[0023] Figure 6 This is a graph showing the IL-6 content in the serum of mice in each experimental group in the relevant test of the present invention.

[0024] Figure 7 This is a graph showing the IL-1β content in the serum of mice in each experimental group in the relevant test of the present invention.

[0025] Figure 8 This is a graph showing the TNF-α content in the serum of mice in each experimental group in the relevant test of the present invention.

[0026] Figure 9 This is a graph showing the MDA content (μmol / gprot) in the liver of mice in each experimental group in the relevant test of the present invention.

[0027] Figure 10 1 is a graph showing the results of CAT activity (U / mgprot) in the liver of mice in each experimental group in the relevant test of the present invention.

[0028] Figure 11 2 is a graph showing the T-SOD activity (U / mgprot) results of each experimental group in the relevant tests of the present invention.

[0029] Figure 12 2 is a graph showing the total antioxidant capacity (T-AOC) (U / mgprot) in the liver of mice in each experimental group in the relevant test of the present invention.

[0030] Figure 13 These are HE-stained sections of the liver of mice in each experimental group of the present invention.

[0031] Figure 14 is a photograph of the composition prepared in Example 1 of the present invention. DETAILED DESCRIPTION

[0032] The "ranges" disclosed herein are defined in terms of lower and upper limits, where a given range is defined by selecting a lower limit and an upper limit, and the selected lower and upper limits define the boundaries of the particular range. Ranges defined in this manner can be inclusive or exclusive of the end values ​​and can be combined arbitrarily, i.e., any lower limit can be combined with any upper limit to form a range. For example, if ranges of 60 to 120 and 80 to 110 are listed for a particular parameter, it is understood that ranges of 60 to 110 and 80 to 120 are also contemplated. Furthermore, if minimum range values ​​of 1 and 2 are listed, and if maximum range values ​​of 3, 4, and 5 are listed, the following ranges are all contemplated: 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, and 2 to 5. In this application, unless otherwise indicated, the numerical range "a to b" is a shorthand representation of any combination of real numbers between a and b, where a and b are both real numbers. For example, a numerical range of "0-5" indicates that all real numbers between "0-5" are listed herein, and "0-5" is simply an abbreviation for these numerical combinations. Furthermore, when a parameter is expressed as an integer ≥ 2, this is equivalent to disclosing that the parameter is, for example, an integer of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.

[0033] Unless otherwise specified, the terms "include" and "comprising" used in this application may be open-ended or closed-ended. For example, "include" and "comprising" may mean that other components not listed may also be included or that only the listed components are included.

[0034] Unless otherwise specified, the term "or" is used in this application to be inclusive. For example, the phrase "A or B" means "A, B, or both A and B." More specifically, the condition "A or B" is satisfied if any of the following conditions are met: A is true (or exists) and B is false (or does not exist); A is false (or does not exist) and B is true (or exists); or both A and B are true (or exist).

[0035] This specific embodiment provides a composition comprising pear paste, the raw materials of which include Qiuyue pear paste, concentrated apple juice, fermented mangosteen juice, sea buckthorn puree and plant composite powder.

[0036] In some embodiments, calculated by weight, the raw materials include 40-50 parts of Qiuyue pear paste, 40-50 parts of concentrated apple juice, 4-8 parts of fermented mangosteen juice, 2-5 parts of sea buckthorn puree, and 0.5-0.7 parts of plant compound powder.

[0037] In some embodiments, the plant composite powder includes tangerine peel powder, lotus seed powder, emblica powder and chrysanthemum powder.

[0038] In some embodiments, in the plant composite powder, the mass ratio of the tangerine peel powder, the lotus seed powder, the emblica powder and the chrysanthemum powder is 1:(1-1.5):(0.5-0.8):(0.3-0.5).

[0039] In addition, this specific embodiment also proposes a method for preparing the above-mentioned composition containing pear paste, comprising the following steps:

[0040] Mix Qiuyue pear paste, concentrated apple juice and fermented mangosteen juice, and cook at 80-85°C for 50-60 minutes; then add sea buckthorn extract and cook at 90-95°C for 20-30 minutes; then add plant composite powder at 105-108°C and stir for 5-10 minutes to obtain the composition containing pear paste.

[0041] In some embodiments, the concentrated apple juice is prepared by the following steps: squeezing apples to obtain apple juice, then adding pectinase to the apple juice, keeping it warm at 45-55°C for enzymatic hydrolysis, then inactivating the enzyme, and then filtering and concentrating to obtain the concentrated apple juice; the amount of pectinase added is 0.2-0.3% of the mass of the apple juice.

[0042] In some embodiments, the fermented mangosteen juice is prepared by the following steps: inoculating Lactobacillus plantarum into mangosteen juice and fermenting at 25-30° C., followed by inactivation to obtain the fermented mangosteen juice.

[0043] In some embodiments, the sea buckthorn puree is obtained by the following steps: mixing the sea buckthorn and water, extracting at 45-50°C, then filtering to obtain a water extract and a filter residue, mixing the filter residue with 50-60% ethanol by mass concentration at 50-55°C and continuing to extract to obtain an ethanol extract, mixing the water extract and the ethanol extract, and then concentrating to obtain the sea buckthorn puree; water extraction obtains water-soluble vitamin C, and ethanol extraction obtains flavonoids.

[0044] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0045] In the present invention, references to “some embodiments”, “this embodiment”, examples, etc. describe a subset of all possible embodiments, but it can be understood that “some embodiments” may be the same subset or different subsets of all possible embodiments, and may be combined with each other without conflict.

[0046] If similar descriptions of "first / second" appear in the application documents, the following explanation is added. In the following description, the terms "first\second\third" are merely used to distinguish similar objects and do not represent a specific order for the objects. It is understandable that "first\second\third" can be interchanged with the specific order or sequence where permitted, so that the embodiments described herein can be implemented in an order other than that illustrated or described herein.

[0047] In this embodiment, the term "and / or" is merely a description of the association relationship between associated objects, indicating that three relationships may exist. For example, object A and / or object B may represent three situations: object A exists alone, object A and object B exist at the same time, and object B exists alone.

[0048] Below, the embodiment of the present application is described. The embodiment described below is exemplary and is only used to explain the present application, and is not to be construed as limiting the present application. Where specific techniques or conditions are not specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. Reagents or instruments used that do not specify the manufacturer are conventional products that can be obtained commercially.

[0049] The Qiuyue pear paste in the following examples was purchased and melted in a 60°C water bath and passed through an 80-mesh sieve before being mixed with concentrated apple juice and fermented mangosteen juice; the plant composite powder was obtained by dry heat sterilization (100°C, 2h).

[0050] Example 1

[0051] This embodiment proposes a composition comprising pear paste. Calculated by mass, the raw materials include 45 parts of Qiuyue pear paste, 45 parts of concentrated apple juice, 6 parts of fermented mangosteen juice, 3 parts of sea buckthorn puree, and 0.6 parts of plant composite powder; the plant composite powder includes tangerine peel powder, lotus seed powder, emblica powder and chrysanthemum powder; the mass ratio of the tangerine peel powder, the lotus seed powder, the emblica powder and the chrysanthemum powder is 1:(1.2):(0.6):(0.4).

[0052] This embodiment also provides a method for preparing the above-mentioned composition containing pear paste, comprising the following steps:

[0053] The composition comprising the pear paste is prepared by mixing Qiuyue pear paste, concentrated apple juice and fermented mangosteen juice, and boiling the mixture at 80°C for 60 minutes until the sugar content reaches 60°Brix; then, adding a roxburghii extract and boiling the mixture at 95°C for 20 minutes until the sugar content reaches 70°Brix; then, adding the plant composite powder and stirring the mixture at 108°C for 5 minutes to obtain the composition;

[0054] The concentrated apple juice is prepared by the following steps: squeezing apples to obtain apple juice, adding pectinase to the apple juice, preserving the juice at 50° C. for 1 hour, inactivating the enzyme, and filtering and concentrating the juice to obtain the concentrated apple juice; the amount of pectinase added is 0.2% by weight of the apple juice;

[0055] The fermented mangosteen juice is prepared by the following steps: inoculating Lactobacillus plantarum into mangosteen juice and fermenting at 30° C. for 12 hours, and then inactivating the mangosteen juice to obtain the fermented mangosteen juice;

[0056] The roxburgh roxburgh puree is obtained by the following steps: mixing the roxburgh roxburgh and water, extracting at 50°C for 1 hour, filtering to obtain a water extract and a filter residue, mixing the filter residue with ethanol with a mass concentration of 50-60% at 50°C and continuing to extract for 1 hour to obtain an ethanol extract, mixing the water extract and the ethanol extract, and then concentrating to 1 / 3 of the original volume to obtain the roxburgh roxburgh puree.

[0057] The obtained composition was subjected to a wire drawing test. When the paste was picked up at 108°C, it was in the form of thin threads without breaking. After hot filling (>90°C), the glass bottle PET packaging bag was sterilized and sealed while hot, inverted for 10 minutes for sterilization, and naturally cooled and solidified to form the texture of the traditional paste. Figure 14 , it can be seen that the composition product prepared in this embodiment is in a paste form.

[0058] Example 2

[0059] This embodiment proposes a composition comprising pear paste. Calculated by mass, the raw materials include 50 parts of Qiuyue pear paste, 40 parts of concentrated apple juice, 8 parts of fermented mangosteen juice, 2 parts of sea buckthorn puree, and 0.5 parts of plant composite powder; the plant composite powder includes tangerine peel powder, lotus seed powder, amla powder, and chrysanthemum powder; the mass ratio of the tangerine peel powder, the lotus seed powder, the amla powder, and the chrysanthemum powder is 1:1:0.8:0.3.

[0060] This embodiment also provides a method for preparing the above-mentioned composition containing pear paste, comprising the following steps:

[0061] The composition comprising the pear paste is prepared by mixing Qiuyue pear paste, concentrated apple juice and fermented mangosteen juice, and boiling the mixture at 85°C for 50 minutes until the sugar content reaches 60°Brix; then, adding a roxburghii extract and boiling the mixture at 90°C for 30 minutes until the sugar content reaches 70°Brix; then, adding the plant composite powder and stirring the mixture at 105°C for 10 minutes to obtain the composition;

[0062] The concentrated apple juice is prepared by the following steps: squeezing apples to obtain apple juice, adding pectinase to the apple juice, preserving the juice at 50° C. for 1 hour, inactivating the enzyme, and filtering and concentrating the juice to obtain the concentrated apple juice; the amount of pectinase added is 0.3% by weight of the apple juice;

[0063] The fermented mangosteen juice is prepared by the following steps: inoculating Lactobacillus plantarum into mangosteen juice and fermenting at 25° C. for 12 hours, and then inactivating the mangosteen juice to obtain the fermented mangosteen juice;

[0064] The roxburgh pear puree is obtained by the following steps: mixing the roxburgh pear and water, extracting at 50°C, filtering to obtain a water extract and a filter residue, mixing the filter residue with 50% ethanol by mass concentration, and continuing to extract at 50°C for 1 hour to obtain an ethanol extract, mixing the water extract and the ethanol extract, and then concentrating to obtain the roxburgh pear puree.

[0065] Example 3

[0066] This embodiment proposes a composition comprising pear paste. Calculated by mass, the raw materials include 40 parts of Qiuyue pear paste, 50 parts of concentrated apple juice, 4 parts of fermented mangosteen juice, 5 parts of sea buckthorn puree, and 0.7 parts of plant composite powder; the plant composite powder includes tangerine peel powder, lotus seed powder, emblica powder and chrysanthemum powder; the mass ratio of the tangerine peel powder, the lotus seed powder, the emblica powder and the chrysanthemum powder is 1:1.5:0.5:0.5.

[0067] This embodiment also provides a method for preparing the above-mentioned composition containing pear paste, comprising the following steps:

[0068] The composition comprising the pear paste is prepared by mixing Qiuyue pear paste, concentrated apple juice and fermented mangosteen juice, and boiling the mixture at 85°C for 50 minutes until the sugar content reaches 60°Brix; then, adding a roxburghii extract and boiling the mixture at 95°C for 20 minutes until the sugar content reaches 70°Brix; then, adding the plant composite powder and stirring the mixture at 105°C for 10 minutes to obtain the composition;

[0069] The concentrated apple juice is prepared by the following steps: squeezing apples to obtain apple juice, adding pectinase to the apple juice, preserving the juice at 45° C. for 1 hour, inactivating the enzyme, and filtering and concentrating the juice to obtain the concentrated apple juice; the amount of pectinase added is 0.3% by weight of the apple juice;

[0070] The fermented mangosteen juice is prepared by the following steps: inoculating Lactobacillus plantarum into mangosteen juice and fermenting at 30° C. for 12 hours, and then inactivating the mangosteen juice to obtain the fermented mangosteen juice;

[0071] The roxburgh roxburgh puree is obtained by the following steps: mixing the roxburgh roxburgh and water, extracting at 50° C. for 1 hour, filtering to obtain a water extract and a filter residue, mixing the filter residue with 60% ethanol by mass concentration at 55° C. and continuing to extract for 1 hour to obtain an ethanol extract, mixing the water extract and the ethanol extract, and then concentrating to obtain the roxburgh roxburgh puree.

[0072] Comparative Example 1

[0073] The difference between this comparative example and Example 1 is that the composition does not contain fermented mangosteen juice, and the fermented mangosteen juice in Example 1 is replaced by an equal amount of concentrated apple juice. The preparation method is the same as that of Example 1.

[0074] The compositions of Example 1 and Comparative Example 1 were subjected to sensory evaluation, active ingredient retention rate and shelf life analysis. The results are shown in Table 1, Table 2 and Table 3.

[0075] Sensory evaluation: sweet-sour ratio, complexity of fruity aroma, and persistence of aftertaste (scored by a professional tasting panel).

[0076] Active ingredients: total phenols, flavonoids, vitamin C content (HPLC / spectrophotometry).

[0077] Shelf life: microorganisms (total colony count), browning degree (ΔE value), flavor stability (GC-MS).

[0078] Table 1 Sensory evaluation results

[0079]

[0080] Table 2 Active ingredient retention rate

[0081] Element Example 1 Comparative Example 1 Rate of change Total phenols (mg / g) 12.5±0.8 10.1±0.6 +23.8％ Flavonoids (mg / g) 8.7±0.4 7.2±0.3 +20.8％ Vitamin C (mg / 100g) 35.2±2.1 28.5±1.8 +23.5％

[0082] From Table 2, we can see that the organic acids (such as lactic acid) produced by the fermentation of mangosteen juice can reduce the oxidation of phenols during cooking.

[0083] Table 3 Accelerated shelf life test (37°C, 90 days)

[0084]

[0085] As can be seen from Table 3, the acidic environment (pH 3.8) of the composition of Example 1 containing fermented mangosteen juice inhibits the Maillard reaction and microorganisms, thereby achieving a better preservation effect.

[0086] The composition of Example 1 has the following advantages over the composition of Comparative Example 1:

[0087] 1. Flavor enhancement: Fermented mangosteen juice significantly enhances the complexity of fruity aroma and the balance of sweetness and sourness (sensory score ↑20%+).

[0088] 2. Function retention: The retention rate of active ingredients such as total phenols and flavonoids is increased by more than 20%.

[0089] 3. Extended shelf life: The rate of browning and flavor deterioration is reduced by about 50%.

[0090] 4. The comprehensive sensory evaluation score increased by 22.4%;

[0091] 5. Total phenol content increased by 23.8%, and vitamin C retention rate increased by 23.5%;

[0092] 6. In the accelerated experiment, the browning degree was reduced by 44.8%, proving that fermented mangosteen juice has a synergistic antioxidant effect.

[0093] It should be noted that, after concentration and boiling (105-108° C.), the ethanol residue in the finished composition of the technical solution of the present application is ≤0.1% (far below the national standard limit of 0.5%).

[0094] Related tests:

[0095] The experimental reagents and materials are shown in Table 4:

[0096] Table 4

[0097]

[0098]

[0099]

[0100] Laboratory Animal Information

[0101] 60 male SPF KM mice, Hunan Slake Jingda Experimental Animal Co., Ltd. (certificate number: ZS-202412310025)

[0102] 3. Experimental method

[0103] 3.1 Anti-inflammatory experiment

[0104] Select Kunming mice (20-22) g, 60, male, stratified random selection according to random number table 10 as control group (i.e. blank group), gavage with sterile physiological saline; The remaining mice were divided into model group (physiological saline, 200 ml / kg), aspirin group (300 mg / kg, i.e. positive group), Example 1 composition high dose group 0.4992 g / 10 g / d, Example 1 composition medium dose group 0.2496 g / 10 g / d and Example 1 composition low dose group 0.1248 g / 10 g / d. Daily gavage with the corresponding drugs, gavage once a day, continuous gavage for 14 days, after the end of administration, the model group, aspirin group, Example 1 composition low dose group, Example 1 composition medium dose group, Example 1 composition high dose group mice were injected intraperitoneally with LPS (5 mg / kg), aspirin was purchased from Bayer Healthcare Limited, batch number BJ82836.

[0105] 3.2 Collection of specimens

[0106] After the last gavage administration, the experimental mice were fasted for 24 h, and then sacrificed immediately after blood collection from the eyeball; immediately take the liver, spleen, kidney, lung and record the weight, and store in a-80℃ refrigerator for standby.

[0107] 3.3 Detection index

[0108] 3.3.1 General state and body weight of mice Each group of mice was observed and recorded daily for general conditions such as mental state, food intake, hair luster, etc.; body weight was measured and recorded every week.

[0109] 3.3.2 ELISA method for detecting IL-1β, IL-13, IL-6, TNF-α content in serum, after blood collection, room temperature standing for 1 h, 4℃, 3000 rpm centrifugation for 10 min, then take the supernatant, strictly according to the operation instruction of ELISA kit.

[0110] 3.3.3 Detection of antioxidant capacity in liver tissue: the liver was rinsed with cold physiological saline, and the filter paper was wiped clean and weighed. Another liver was taken and prepared into 10% homogenate with physiological saline, and the supernatant was taken and stored at-20℃ for testing. The 10% homogenate supernatant of liver tissue was taken, and the total antioxidant capacity (T-AOC), malondialdehyde (MDA) content, superoxide dismutase (SOD) activity and catalase (CAT) activity were detected according to the instruction manual of the kit.

[0111] 3.3.4 Pathological Observation of Liver Tissue Liver tissue was removed from 4% tissue fixative and sliced ​​using HE staining. After slice preparation, the pathological morphology of the liver was observed under a light microscope.

[0112] Experimental results

[0113] 1. Organ weight coefficient of each group

[0114] The organ coefficient is a commonly used indicator in experiments. Under normal circumstances, the ratio of each organ to body weight is relatively constant. However, when damaged, organ weight can change, and therefore the organ coefficient also changes accordingly. Toxicologists generally believe that a decrease in the organ coefficient indicates atrophy or degenerative changes in the organ, while an increase in the organ coefficient may indicate congestion, edema, or hypertrophy. Acute inflammation can cause congestion and edema in the liver, spleen, lungs, and kidneys, primarily through mechanisms including vasodilation, increased vascular permeability, and inflammatory cell infiltration. Table 5 shows the changes in the liver coefficient, spleen coefficient, lung coefficient, and lung coefficient for each group of mice.

[0115] From Table 5 and Figure 1 It can be seen that the liver coefficient of the model group mice was significantly higher than that of the normal group (P<0.05), and the combination can reduce the liver coefficient. The liver coefficient decreases more significantly with the increase of the dose; the high dose can significantly reduce the liver coefficient (P<0.05). Table 5, Table 6, Table 7 or Figure 1-13 The low-dose group of pears corresponds to the low-dose group of the composition of Example 1, the medium-dose group of pears corresponds to the medium-dose group of the composition of Example 1, and the high-dose group of pears corresponds to the high-dose group of the composition of Example 1.

[0116] From Table 5 and Figure 2 It can be seen that the spleen coefficients of the mice in the model group were significantly higher than those in the normal group (P<0.05). The combination can reduce the spleen coefficient, and the spleen coefficient decreases more significantly with increasing doses; high doses can significantly reduce the spleen coefficient (P<0.05).

[0117] From Table 5 and Figure 3 It can be seen that the lung coefficients of mice in the model group were significantly higher than those in the normal group (P<0.05). The combination was able to reduce the lung coefficient, and the reduction in the lung coefficient became more obvious as the dose increased; a high dose was able to significantly reduce the lung coefficient (P<0.01).

[0118] From Table 5 and Figure 4 It can be seen that the kidney coefficients of the mice in the model group were significantly higher than those in the normal group (P<0.05). The combination can reduce the kidney coefficient, and the reduction in the kidney coefficient becomes more obvious as the dose increases; a high dose can significantly reduce the kidney coefficient (P<0.05).

[0119] The liver, spleen, lung, and kidney coefficients of the model group mice were significantly higher than those of the normal group (P < 0.05). The composition was able to reduce the liver, spleen, lung, and kidney coefficients, and the high dose of the composition was able to reduce the organ coefficients (P < 0.05). These results indicate that the composition of Example 1 can significantly alleviate congestion and edema in the liver, spleen, lungs, and kidneys caused by inflammation.

[0120] Table 5 Organ coefficients of each group

[0121]

[0122] Note: Compared with the blank group, the model group showed ▲P<0.05; compared with the model group, the low, medium, and high doses of the combination showed *P<0.05, **P<0.01, and ***P<0.001. It should be noted that some experimental groups had fewer than 10 mice because some mice died during gavage.

[0123] 2. Analysis of IL-13, IL-6, IL-1β, and TNF-α in mouse serum

[0124] Combined with Table 6 and Figure 5-8 IL-13 (Interleukin-13) is a cytokine mainly produced by Th2 cells, which plays an important role in immune regulation, inflammatory response and allergic diseases. It shows an upward regulation trend in acute inflammation. The expression of IL-13 in the model group mice was significantly increased compared with the normal group (P<0.05), indicating that the model group mice had more obvious inflammatory symptoms than the normal group mice. The IL-13 expression in the low, medium and high dose groups of the composition of Example 1 decreased to varying degrees compared with the model, and the degree of decrease increased with the increase of the dose; the medium and high doses of the composition of Example 1 can significantly reduce the expression of IL-13 (P<0.05), indicating that the composition can inhibit the increase in the level of cytokine IL-13 in young mice with acute inflammation and play an anti-inflammatory effect.

[0125] Table 6 IL-13, IL-6, IL-1β, and TNF-α levels in mouse serum

[0126]

[0127]

[0128] Note: Compared with the blank group, the model group ▲P<0.05; compared with the model group, the low, medium and high doses of pear paste, *P<0.05, **P<0.01.

[0129] IL-6 (Interleukin-6) is a key cytokine in acute inflammation, with pleiotropic functions; it plays an important role in the initiation, maintenance and resolution of inflammatory response, and is also involved in immune regulation and tissue repair; a pleiotropic cytokine produced by monocytes, macrophages, T lymphocytes and other cell types, significantly up-regulated during infection and inflammation. The expression of IL-6 in the model group was significantly higher than that in the normal group (P<0.05), indicating that the inflammatory symptoms of the model group were more obvious than those of the normal group. The expression of IL-6 in the low, medium and high dose groups of Example 1 composition was decreased to varying degrees compared with the model, and the degree of decrease increased with the increase of the dose; the high dose of Example 1 composition could significantly reduce the expression of IL-6 (P<0.05), indicating that Example 1 composition could inhibit the increase of IL-6 level in young acute inflammatory mice, thereby playing an anti-inflammatory effect.

[0130] IL-1β (Interleukin-1β) is a key pro-inflammatory cytokine in acute inflammation, which plays a core role in the initiation, amplification and maintenance of inflammatory response. It is mainly produced by macrophages, monocytes and neutrophils, regulated by NF-κB and NLRP3 inflammasome signaling pathway, and the pro-inflammatory effect of IL-1β is of great significance in acute inflammation, and is significantly up-regulated during inflammation. The expression of IL-1β in the model group was significantly increased compared with the blank group (P<0.05), and the inflammatory symptoms of the model group were obvious. The medium and high dose groups of Example 1 composition could significantly (P<0.05) reduce the expression of IL-1β in mice, indicating that Example 1 composition could inhibit the increase of IL-6 level in young acute inflammatory mice, thereby playing an anti-inflammatory effect.

[0131] TNF-α is a pleiotropic pro-inflammatory cytokine, belonging to the TNF ligand superfamily, which plays different roles in regulating various developmental and immune processes, including inflammation, differentiation, lipid metabolism and apoptosis, and is related to various diseases. The expression of TNF-α in the model group was significantly increased compared with the blank group (P<0.05), and the inflammatory symptoms of the model group were obvious. The expression of TNF-α in the low, medium and high dose groups of Example 1 composition was decreased to varying degrees compared with the model, and the degree of decrease increased with the increase of the dose; the medium and high dose groups of Example 1 composition could significantly (P<0.05) reduce the expression of TNF-α in mice, indicating that Example 1 composition could inhibit the increase of TNF-α level in young acute inflammatory mice, thereby playing an anti-inflammatory effect.

[0132] 3. Antioxidant capacity of mice

[0133] The antioxidant capacity is closely related to acute inflammation. When the body has acute inflammation, inflammatory cells produce a large number of free radicals such as active oxygen, which can trigger oxidative stress. If the antioxidant capacity is insufficient, free radicals will attack cells and tissues, and aggravate inflammatory damage. On the other hand, stronger antioxidant capacity can clear excessive free radicals, reduce oxidative stress, and help to alleviate inflammatory response and protect the body. At the same time, antioxidant substances can also play an important regulatory role in the occurrence, development and outcome of acute inflammation by regulating inflammatory signaling pathways and other mechanisms, and maintaining the stability of the body's internal environment. Therefore, the liver grinding solution was tested for antioxidant capacity in this study, and the experimental results are shown in Table 7 and Figure 9-12 .

[0134] Table 7 Antioxidant capacity detection results in mouse liver

[0135]

[0136]

[0137] Note: Compared with the blank group, the model group▲P<0.05; compared with the model group, the low, medium and high doses of pear paste, *P<0.05, **P<0.01, ***P<0.001.

[0138] In acute inflammation, the level of MDA (malondialdehyde) usually increases. MDA is a product of lipid peroxidation and is often used as a marker of oxidative stress damage. In the inflammatory response, the generation of reactive oxygen species (ROS) increases, leading to lipid peroxidation of cell membranes, and thus increasing the level of MDA. The MDA content of the LPS model group was significantly higher than that of the blank group (P<0.05), and the MDA content of the low, medium and high dose groups of the composition of Example 1 was lower than that of the LPS model group, and the MDA content of the medium and high dose groups was significantly lower (P<0.05).

[0139] During acute inflammation, due to the aggravation of oxidative stress, the regulatory effect of inflammatory factors, the influence of metabolic reprogramming, and the dynamic balance of cell damage and repair. These factors work together to inhibit the expression and activity of CAT. The CAT content of the LPS model group was significantly lower than that of the blank group (P<0.05), and the CAT content of the low, medium and high dose groups of the composition of Example 1 was significantly higher than that of the LPS model group (P<0.05).

[0140] During acute inflammation, total superoxide dismutase (T-SOD) activity in the liver is typically suppressed due to increased oxidative stress, regulatory effects of inflammatory factors, and imbalances in the Nrf2 signaling pathway. The total superoxide dismutase (T-SOD) activity in the LPS model group was significantly lower than that in the blank group (P < 0.05). Compared with the LPS model group, the total superoxide dismutase (T-SOD) activity in the low-, medium-, and high-dose groups of the composition of Example 1 was significantly increased (P < 0.05).

[0141] In acute inflammation, the activity of total antioxidant capacity (T-AOC) is usually suppressed. In acute inflammatory conditions, the body's antioxidant capacity may be weakened, leading to increased levels of oxidative stress. The total antioxidant capacity (T-AOC) of the LPS model group was significantly lower than that of the blank group (P < 0.05). Compared with the LPS model group, the total antioxidant capacity (T-AOC) of the low, medium, and high-dose groups of the composition of Example 1 increased, and the total antioxidant capacity (T-AOC) of the medium and high-dose groups of the composition of Example 1 increased significantly (P < 0.05).

[0142] 4. Liver HE staining sections

[0143] Combine Figure 13 HE staining was used to observe the degree of liver damage. The results showed that the liver lobules of the blank group mice were intact, with uniform nuclei, clear edges and uniform distribution, and no abnormal pathological changes were observed. Compared with the blank group mice, the liver tissue cells of the model group mice showed obvious swelling, and there was diffuse inflammatory cell infiltration near the liver lobules with irregular distribution, indicating that the model group mice had obvious inflammatory symptoms. The pathological symptoms of the mice in the positive drug group were significantly improved, the degree of liver tissue cell swelling was significantly improved, the cell distribution was relatively uniform, and the inflammatory cell infiltration phenomenon was alleviated. The degree of liver tissue cell swelling of the mice in the high-dose group of the composition of Example 1 was significantly improved, and the inflammatory symptoms were relatively improved. The degree of liver tissue cell swelling of the mice in the medium-dose group of the composition of Example 1 was improved, and the inflammatory symptoms were improved to a certain extent, but the cells still had swelling. The degree of liver tissue cell swelling of the mice in the low-dose group of the composition of Example 1 was slightly improved. It should be noted that the compositions of Examples 2 and 3 have technical effects comparable to those of the composition of Example 1.

[0144] The specific embodiments of the present invention described above do not limit the scope of protection of the present invention. Any other corresponding changes and modifications made based on the technical concept of the present invention should be included in the scope of protection of the claims of the present invention.

Claims

1. A composition comprising pear paste, characterized in that The raw materials include Qiuyue pear paste, concentrated apple juice, fermented mangosteen juice, sea buckthorn puree and plant compound powder; the plant compound powder includes tangerine peel powder, lotus seed powder, amla powder and chrysanthemum powder.

2. The composition comprising pear paste according to claim 1, wherein Calculated by mass, the raw materials include 40-50 parts of Qiuyue pear paste, 40-50 parts of concentrated apple juice, 4-8 parts of fermented mangosteen juice, 2-5 parts of sea buckthorn puree, and 0.5-0.7 parts of plant compound powder.

3. The composition comprising pear paste according to claim 1, wherein In the plant composite powder, the mass ratio of the tangerine peel powder, the lotus seed powder, the emblica powder and the chrysanthemum powder is 1:(1-1.5):(0.5-0.8):(0.3-0.5).

4. A method for preparing a composition comprising pear paste according to any one of claims 1 to 3, characterized in that: The following steps are involved: Qiuyue pear paste, concentrated apple juice and fermented mangosteen juice are mixed and boiled at 80-85° C.; then, a sea buckthorn extract is added and boiled at 90-95° C.; then, plant composite powder is added and stirred at 105-108° C. to obtain the composition containing pear paste.

5. The method for preparing the composition comprising pear paste according to claim 4, wherein The cooking time at 80-85℃ is 50-60 minutes.

6. The method for preparing the composition comprising pear paste according to claim 4, wherein: The cooking time at 90-95° C. is 20-30 minutes; and / or the stirring time at 105-108° C. is 5-10 minutes.

7. The method for preparing the composition comprising pear paste according to claim 4, wherein: The concentrated apple juice is prepared by the following steps: squeezing apples to obtain apple juice, adding pectinase to the apple juice, preserving the juice at 45-55° C. for enzymolysis, inactivating the enzyme, and filtering and concentrating the juice to obtain the concentrated apple juice.

8. The method for preparing the composition comprising pear paste according to claim 6, wherein: The added amount of the pectinase is 0.2-0.3% of the mass of the apple juice.

9. The method for preparing a composition comprising pear paste according to claim 4, wherein: The fermented mangosteen juice is prepared by the following steps: inoculating Lactobacillus plantarum into mangosteen juice, fermenting at 25-30° C., and then inactivating the mangosteen juice to obtain the fermented mangosteen juice.

10. The method for preparing a composition comprising pear paste according to claim 4, wherein: The roxburgh roxburgh puree is obtained by the following steps: mixing the roxburgh roxburgh and water, extracting at 45-50° C., filtering to obtain a water extract and a filter residue, mixing the filter residue and ethanol with a mass concentration of 50-60% at 50-55° C., and continuing to extract to obtain an ethanol extract, mixing the water extract and the ethanol extract, and then concentrating to obtain the roxburgh roxburgh puree.

Images